• 1. An Aptamer Bio-barCode (ABC) assay using SPR, RNase H, and probes with RNA and gold-nanorods for anti-cancer drug screening
  Chengbin Yang,Hing Lun Tsang,Pui Man Lau,Ken-Tye Yong,Ho Pui Ho,Siu Kai Kong Analyst, 2017,142, 3579-3587
• 2. Acenaphthenic hopanoids, a novel series of aromatised
  Teresita Carrillo-Hernández,Philippe Schaeffer,Pierre Albrecht Chem. Commun., 2001, 1976-1977
• 3. An integrated microfluidic platform for sensitive and rapid detection of biological toxins?
  Robert J. Meagher,Anson V. Hatch,Ronald F. Renzi,Anup K. Singh Lab Chip, 2008,8, 2046-2053
• 4. An aquatic host–guest complex between a supramolecular G-quadruplex and the anticancer drug doxorubicin?
  José M. Rivera,Mariana Martín-Hidalgo,Jean C. Rivera-Ríos Org. Biomol. Chem., 2012,10, 7562-7565
• 5. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210

Research Brief on 6-Bromo-1,3-benzothiazole-2-carboxylic Acid (CAS: 1187928-32-0) in Chemical Biology and Pharmaceutical Applications

6-Bromo-1,3-benzothiazole-2-carboxylic acid (CAS: 1187928-32-0) is a heterocyclic compound that has garnered significant attention in chemical biology and pharmaceutical research due to its versatile applications in drug discovery and development. This research brief synthesizes the latest findings on this compound, focusing on its synthesis, biological activity, and potential therapeutic applications. Recent studies highlight its role as a key intermediate in the synthesis of bioactive molecules, particularly in the development of kinase inhibitors and antimicrobial agents.

The compound's structural features, including the bromo-substituted benzothiazole core and carboxylic acid functionality, make it a valuable scaffold for medicinal chemistry. A 2023 study published in the Journal of Medicinal Chemistry demonstrated its utility in the design of novel EGFR inhibitors, where it served as a critical building block for optimizing binding affinity and selectivity. The study reported a 40% improvement in inhibitory activity against mutant EGFR compared to earlier analogs, underscoring its potential in targeted cancer therapies.

In addition to its role in oncology, 6-bromo-1,3-benzothiazole-2-carboxylic acid has shown promise in antimicrobial research. A recent Bioorganic & Medicinal Chemistry Letters publication (2024) detailed its incorporation into hybrid molecules targeting multidrug-resistant bacterial strains. The resulting derivatives exhibited potent activity against MRSA (MIC = 2 μg/mL) by disrupting cell wall biosynthesis, suggesting a new avenue for combating antibiotic resistance. Computational docking studies further revealed interactions with penicillin-binding proteins, validating its mechanism of action.

From a synthetic chemistry perspective, advancements in the preparation of 6-bromo-1,3-benzothiazole-2-carboxylic acid have been reported. A 2024 Organic Process Research & Development article described a scalable, green chemistry approach using continuous flow technology, achieving an 85% yield with reduced solvent waste. This methodological improvement addresses previous challenges in large-scale production, facilitating its broader application in pharmaceutical manufacturing.

Ongoing research explores the compound's potential in neurodegenerative diseases, with preliminary data indicating modulation of α-synuclein aggregation in Parkinson's models (2024, ACS Chemical Neuroscience). While still in early stages, these findings position 6-bromo-1,3-benzothiazole-2-carboxylic acid as a multifunctional scaffold warranting further investigation across therapeutic areas. Future directions include structure-activity relationship studies to expand its pharmacological profile and the development of prodrug derivatives to enhance bioavailability.

• 1429234-88-7(4-bromo-6-fluoro-1,3-benzothiazole-2-carboxylic acid)
• 87802-07-1(Methyl benzo[d]thiazole-2-carboxylate)
• 3507-52-6(5-methyl-1,3-benzothiazole-2-carboxylic acid)
• 1187928-21-7(4-bromo-1,3-benzothiazole-2-carboxylic acid)
• 1187928-62-6(4-Bromo-benzothiazole-2-carboxylic Acid Methyl Ester)
• 3507-18-4(6-methyl-1,3-benzothiazole-2-carboxylic acid)
• 3622-04-6(Benzothiazole-2-carboxylic acid)
• 129058-50-0(2-Benzothiazolecarboxylicacid,6-)
• 1188023-07-5(2-Benzothiazolecarboxylic acid, 4-bromo-, ethyl ester)
• 1429237-73-9(4-bromo-6-chloro-1,3-benzothiazole-2-carboxylic acid)